The Institute for Bioinformatics was established in 2010 as the latest member of the Biocenter at the Medical University of Innsbruck and it is dedicated to supporting basic research and teaching in bioinformatics and computational biology. The Institute for Bioinformatics is well equipped both for data processing and management as well as for computational analysis of a broad range of data types, including next-generation sequencing data, proteomics and metabolomics data, and image analysis. It has a state-of-the-art computational infrastructure, which is dedicated to bioinformatics analysis. A number of analytical pipelines, databases and software tools developed by the laboratory and others are installed and continuously maintained.
The research of the Institute of Bioinformatics focuses on cancer immunology and aims at deciphering tumor-immune cell interaction by means of a combined computational-experimental approach. It specifically looks at the question of how the immune system shapes the mutation spectrum of the tumor, both during progression and after treatment, in patients with colorectal cancer. The institute uses tumor-derived organoids, perturbation experiments and multimodal analysis, including next-generation sequencing, phosphoproteomics and imaging mass cytometry to facilitate precision immuno-oncology.
About Innoplexus AG
Innoplexus is a leading global AI-based platform for drug discovery and development with over 250 employees and 120+ patent applications including 41 granted patents in artificial intelligence, machine learning, and blockchain technologies. Innoplexus’ solutions can generate real-time insights from hundreds of terabytes of structured and unstructured private and public data, thereby, facilitating continuous, informed decision-making for its customer base at an unprecedented speed. Founded in 2015, Innoplexus AG is headquartered in Eschborn, Germany, with offices in Pune, India, as well as Iselin, and San Francisco, United States.
Contact
Secarna Pharmaceuticals GmbH & Co. KG
Alexander Gebauer, MD, PhD
CEO
alexander.gebauer@secarna.com
Secarna Pharmaceuticals GmbH & Co. KG
Am Klopferspitz 19
82152 Planegg/Martinsried
Tel.: +49 (0)89 215 46 375
For media enquiries:
Anne Hennecke/Vera Lang
MC Services AG
secarna@mc-services.eu
Tel.: +49 (0)211.52 92 52 15